Take2 Health Partnering with Pascific Laboratories to Offer Early Cancer Detection Test
Take2 Health (“Take2”) and Pascific Laboratories are working together to offer the Take2 Prophecy™ Test for Nasopharyngeal Cancer (“NPC”) in the Philippines, as the first step of rolling out the operation.
Pascific Laboratories is a healthcare group focusing on improving access to precision healthcare with operations across the Philippines, Singapore, and India. Take2 is honoured to work alongside the distinguished team of researchers and clinicians at Pascific Laboratories who share the same vision with us.
The age-specific NPC incidence rate in the Philippines ranks 7th among all Asian countries[1]. By joining hands, it is expected to raise the awareness of early NPC detection and improve the overall health of the local communities through enabling in-time diagnosis and treatment in place.
[1] Neda M, Mahshid G, Abdollah MH, Bahman K, Hamid S. “Epidemiology and Inequality in the Incidence and Mortality of Nasopharynx Cancer in Asia.” Osong Public Health and Research Perspectives. 2016;7(6):360-372. doi: 10.1016/j.phrp.2016.11.002.
More Latest News
Nasopharyngeal Cancer Screening Results May “Predict” Development of Related Cancer and Improve Early Diagnosis, CUHK Study Finds
A recent study conducted by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has shown that individuals with detectable plasma Epstein–Barr virus (EBV) DNA but without an immediately identifiable nasopharyngeal cancer (NPC) after further investigation with nasal endoscopic examination and magnetic resonance imaging (MRI), have a higher risk of developing NPC in 3 to 5 years, up to 17 times higher than those tested “negative” in the test. The non-invasive liquid biopsy techniques not only could be used for early cancer detection but may also indicate the risk for future cancer development.
Promoting NPC Awareness across the City
Joining Hands with Bowtie to Sponsor the Take2 Prophecy™ Test for Nasopharyngeal Cancer to the High-risk Group
Awarded as The Company with the Most Investment Potential & The Top Breakthrough Innovation
Take2 Health are privileged to have participated in the first ZAODX World Conference on Early Detection of Cancer, and are very honoured to be awarded as The Company with the Most Investment Potential (金篩獎‧最具投資價值潛力企業) as well as The Top Breakthrough Innovation (金篩獎‧突破性創新獎)
